Lakefront Biotherapeutics (LKFT) Other Non Operating Income (2014 - 2025)

Lakefront Biotherapeutics (LKFT) has reported Other Non Operating Income for 11 consecutive years, with $17.2 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Other Non Operating Income fell 8.92% year-over-year to $17.2 million; the TTM figure through Dec 2025 stood at $51.0 million (down 47.31% YoY), while the FY2025 annual figure was $52.6 million, down 44.92% from the prior year.
• Other Non Operating Income advanced to $17.2 million in Q4 2025 per LKFT's latest filing, from $10.8 million in the prior quarter.
• Across five years, Other Non Operating Income topped out at $43.7 million in Q1 2021 and bottomed at -$76.0 million in Q4 2021.
• Historically, Other Non Operating Income has averaged $11.1 million across 5 years, with a median of $15.3 million in 2025.
• Annual changes were most pronounced in 2022 — Other Non Operating Income sank 109.0% — and 2023, when it soared 2702.26%.
• Lakefront Biotherapeutics' Other Non Operating Income stood at -$76.0 million in 2021, then soared by 116.25% to $12.3 million in 2022, then surged by 105.69% to $25.4 million in 2023, then declined by 25.51% to $18.9 million in 2024, then dropped by 8.92% to $17.2 million in 2025.
• Business Quant data shows LKFT's Other Non Operating Income at $17.2 million in Q4 2025, $10.8 million in Q3 2025, and $10.6 million in Q2 2025.